These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11816336)

  • 21. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors.
    Tanis BC; Rosendaal FR
    Semin Vasc Med; 2003 Feb; 3(1):69-84. PubMed ID: 15199494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of oral contraceptives and cardiovascular disease.
    Vandenbroucke JP; Helmerhorst FM; Rosendaal FR
    Ann Intern Med; 1998 Nov; 129(9):747. PubMed ID: 9841612
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives.
    Alhenc-Gelas M; Plu-Bureau G; Guillonneau S; Kirzin JM; Aiach M; Ochat N; Scarabin PY
    J Thromb Haemost; 2004 Sep; 2(9):1594-600. PubMed ID: 15333036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Third generation oral contraceptives and the risk of venous thromboembolism: management of the uncertainty.
    Maling TJ
    N Z Med J; 1999 Aug; 112(1094):305-7. PubMed ID: 10493438
    [No Abstract]   [Full Text] [Related]  

  • 25. Risk of acute myocardial infarction and low-dose combined oral contraceptives.
    Jick H; Jick S; Myers MW; Vasilakis C
    Lancet; 1996 Mar; 347(9001):627-8. PubMed ID: 8596366
    [No Abstract]   [Full Text] [Related]  

  • 26. Prothrombin 20210A polymorphism and third generation oral contraceptives--a case report of coeliac axis thrombosis and splenic infarction.
    Gould J; Deam S; Dolan G
    Thromb Haemost; 1998 Jun; 79(6):1214-5. PubMed ID: 9657451
    [No Abstract]   [Full Text] [Related]  

  • 27. [Risk and benefits of using contraceptives of third generation].
    Uchikova E; Milchev N
    Akush Ginekol (Sofiia); 2004; 43(1):59-62. PubMed ID: 15168658
    [No Abstract]   [Full Text] [Related]  

  • 28. Oral contraceptives and venous thromboembolism.
    Lawrenson R; Farmer R
    N Z Med J; 1997 Feb; 110(1038):63. PubMed ID: 9076294
    [No Abstract]   [Full Text] [Related]  

  • 29. Desogestrel-only pill (Cerazette).
    Faculty of Family Planning & Reproductive Health Care, Clinical Effectiveness Unit
    J Fam Plann Reprod Health Care; 2003 Jul; 29(3):162-4. PubMed ID: 12885316
    [No Abstract]   [Full Text] [Related]  

  • 30. [Third-generation pill].
    Helmerhorst F; Vandenbroucke JP
    Ned Tijdschr Geneeskd; 2000 Apr; 144(17):818. PubMed ID: 10858107
    [No Abstract]   [Full Text] [Related]  

  • 31. Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group.
    de Bruijn SF; Stam J; Vandenbroucke JP
    Lancet; 1998 May; 351(9113):1404. PubMed ID: 9593414
    [No Abstract]   [Full Text] [Related]  

  • 32. [Contraceptives and breast cancer (author's transl)].
    Mauvais-Jarvis P; Kuttenn F
    Contracept Fertil Sex (Paris); 1976 Sep; 4(5):343-8. PubMed ID: 992191
    [No Abstract]   [Full Text] [Related]  

  • 33. Hormone-based contraceptive therapy and risk of venous thromboembolism in young women.
    Roberts H
    Clin Adv Hematol Oncol; 2010 May; 8(5):307-9. PubMed ID: 20551888
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pregnancies and terminations after 1995 warning about third-generation oral contraceptives.
    Jick SS; Vasilakis C; Jick H
    Lancet; 1998 May; 351(9113):1404-5. PubMed ID: 9593415
    [No Abstract]   [Full Text] [Related]  

  • 36. [Contraception and arterial hypertension].
    Corvol P; Millet D; Keledjian P
    Acquis Med Recent; 1977; ():177-80. PubMed ID: 910596
    [No Abstract]   [Full Text] [Related]  

  • 37. [Oral contraceptives and risk of myocardial infarction].
    Sørensen MB; Ottesen BS
    Ugeskr Laeger; 2002 Apr; 164(18):2415-6. PubMed ID: 12024850
    [No Abstract]   [Full Text] [Related]  

  • 38. [The Marvelon issue and confidence towards oral contraceptives].
    Rygh LH; Hannisdal K
    Tidsskr Nor Laegeforen; 1997 Feb; 117(4):558-9. PubMed ID: 9148461
    [No Abstract]   [Full Text] [Related]  

  • 39. [Possible interference of synthetic estroprogestins with thyroid hormone production].
    Paggi A; Leri O; Evangelista M; Manfredi F; Coarelli C; Loiacono C; Cassone R
    Clin Ter; 1981 Aug; 98(4):349-63. PubMed ID: 7285541
    [No Abstract]   [Full Text] [Related]  

  • 40. Transitory reduction of platelet aggregation with the use of etonogestrel implant in healthy women.
    Vieira CS; Ferriani RA; Garcia AA; Gomes MK; Azevedo GD; Silva de Sá MF
    Thromb Haemost; 2005 Sep; 94(3):682-3. PubMed ID: 16268492
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.